NCT00484432View on ClinicalTrials.gov

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Ovarian Cancer Metastatic Recurrent
Interventions
DRUG

NGR-hTNF

NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs

DRUG

doxorubicin

Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²

Trial Locations (2)

Unknown

Fondazione San Raffaele del Monte Tabor, Milan

00168

Policlinico Universitario A. Gemelli, Rome

Sponsors
All Listed Sponsors
lead

AGC Biologics S.p.A.

INDUSTRY